SMS Pharmaceuticals Intrinsic Value
SMS Pharmaceuticals intrinsic value. SMS Pharmaceuticals (SMSPHARMA) median intrinsic value is ₹845.86 from 9 valuation models (range ₹143–₹1195), vs current price ₹477.85 — +77.0% upside (Trading Below Calculated Value), margin of safety 43.5%. Compare with SMSPHARMA fair value estimate to assess whether the stock is under or overvalued.
SMSPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
SMS Pharmaceuticals intrinsic value across 9 models vs current price ₹477.85 — upside/downside and value range per method. For current market price and key ratios, visit SMS Pharmaceuticals stock price NSE.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹315.04 | ₹252.03 - ₹378.05 | -34.1% | EPS: ₹14.32, Sector P/E: 22x |
| Book Value Method | asset | ₹1194.62 | ₹1075.16 - ₹1314.08 | +150.0% | Book Value/Share: ₹873.33, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹955.70 | ₹860.13 - ₹1051.27 | +100.0% | Revenue/Share: ₹1071.11, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹955.70 | ₹860.13 - ₹1051.27 | +100.0% | EBITDA: ₹172.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹845.86 | ₹676.69 - ₹1015.03 | +77.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹143.35 | ₹129.01 - ₹157.69 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹221.24 | ₹199.12 - ₹243.36 | -53.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹955.70 | ₹860.13 - ₹1051.27 | +100.0% | ROE: 16.8%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹530.46 | ₹477.41 - ₹583.51 | +11.0% | EPS: ₹14.32, BVPS: ₹873.33 |
SMSPHARMA Intrinsic Value vs Market Price — All Valuation Models
SMS Pharmaceuticals fair value range ₹143–₹1195 vs current market price ₹477.85 across 9 valuation models. Read SMS Pharmaceuticals dividend policy for the complete payout history and dividend yield track record.
SMSPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
SMS Pharmaceuticals median intrinsic value ₹845.86, current price ₹477.85 — Trading Below Calculated Value by 77.0%, margin of safety 43.5%.
What is the intrinsic value of SMSPHARMA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of SMS Pharmaceuticals (SMSPHARMA) is ₹845.86 (median value). With the current market price of ₹477.85, this represents a +77.0% variance from our estimated fair value.
The valuation range spans from ₹143.35 to ₹1194.62, indicating ₹143.35 - ₹1194.62.
Is SMSPHARMA undervalued or overvalued?
Based on our multi-method analysis, SMS Pharmaceuticals (SMSPHARMA) appears to be trading below calculated value by approximately 77.0%.
SMSPHARMA Financial Health — Key Ratios vs Industry Benchmarks
SMS Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.85 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 16.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 17.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.71x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
SMSPHARMA Cash Flow Quality — Operating & Free Cash Flow
SMS Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹82 Cr | ₹21 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹50 Cr | ₹24 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹23 Cr | ₹8 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹45 Cr | ₹32 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹90 Cr | ₹14 Cr | Positive Free Cash Flow | 7/10 |